DT-109 Reverses MASH in Animal Studies
An experimental drug called DT-109 has successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models by targeting harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver, according to findings published in The Journal of Clinical Investigation. MASH affects approximately 7% of the global population, causing excess fat accumulation, cellular damage, and inflammation in the liver that can progress to cirrhosis, liver failure, and liver cancer. Effective treatments for the condition remain limited despite recent therapeutic advancements.
Eugene Chen Explains Gut Protection Mechanisms
Researchers at Michigan Medicine discovered that the compound alters gut microbiota to interrupt the biological chain reaction responsible for liver damage. Scientists confirmed that MASH is strongly driven by an overgrowth of Clostridium perfringens, a bacterium inside the intestines that generates ammonia. Elevated ammonia levels weaken the gut’s inner protective lining, allowing microbial toxins to enter the bloodstream and travel to the liver. Once inside the liver, these toxins trigger immune defenses, including the overactivation of CD8+ T cells, which accelerate inflammatory tissue injury.
We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression,
said Eugene Chen, M.D., Ph.D., senior author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School.
This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH,
Chen added.
Jifeng Zhang Details Gut-Liver Axis Dynamics
Through experiments involving both mice and nonhuman primates, researchers tracked how DT-109 reinforces the intestinal barrier. The glycine-based tripeptide lowered Clostridium perfringens populations and reduced ammonia production inside the digestive tract. These structural improvements limited the systemic translocation of pro-inflammatory microbial products. Nonhuman primates were included in the testing because their gut microbiomes and liver biology closely mirror human physiology.
DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis,
said Jifeng Zhang, Ph.D., co-author and research professor of cardiovascular medicine at the U-M Medical School. We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further.
Elliot Tapper Outlines Next Steps for Human Trials
Beyond fatty liver disease, previous studies show that DT-109 reduces atherosclerotic plaque formation and prevents vascular calcification in nonhuman primates, pointing to potential cardiovascular benefits. Researchers are also examining whether the intestinal barrier repair properties could assist patients with inflammatory bowel disease, such as Crohn’s disease and ulcerative colitis. However, the compound remains strictly experimental, and investigators have not yet tested its safety or efficacy in human clinical trials.
This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat,
said Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine. What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health – of course we are excited about these developments.
Future evaluations will focus on advancing DT-109 toward human clinical trials to establish dosing safety and therapeutic utility. The University of Michigan holds the patent for the compound and has licensed it to Diapin Therapeutics, a company in which Chen and the university maintain ownership interests. Diapin supplied the drug used for the research.
Frequently Asked Questions About DT-109
What chemical structure does DT-109 possess?
DT-109 is a glycine-based tripeptide, meaning it is a small molecule constructed from three amino acids, which serve as the fundamental building blocks of proteins.
Which specific bacterium does the drug target in the intestines?
The compound reduces the growth of Clostridium perfringens, a specific bacterial strain that produces high levels of ammonia inside the digestive tract.
Which institutions approved the human protocols cited alongside the study?
Study protocols received approvals from the First Affiliated Hospital of Xi’an Jiaotong University under approval number XJTU1AF2023LSK330, the Institutional Review Board of Jinan University under approval number 2016-017, and the University of Hong Kong/Hospital Authority Hong Kong West Cluster under approval number UW 20-700.